BackPharmicell , Ltd. Overview

Pharmicell , Ltd. EBIT

Track Pharmicell , Ltd.'s EBIT ($48B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$11.91B
↑ 46.31% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

$47.75B
↑ 61.67% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Pharmicell , Ltd. (005690.KS) FAQ

Pharmicell , Ltd. posts a EBIT of $48B as of September 2026. That compares with $30B in the prior-year period — up 61.7% year over year. That is below the Healthcare sector average of $1.9T. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Pharmicell , Ltd.'s EBIT was $30B. The latest reading is $48B — a 61.7% year-over-year increase (period ending September 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a EBIT near $1.9T is typical. Pharmicell , Ltd.'s $48B is lower that level. That is roughly 97.5% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of Pharmicell , Ltd.'s financial statement story. At $48B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for 005690.KS's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $1.9T), and (3) consistency with growth and profitability. This page covers the first two; Pharmicell , Ltd.'s other metric pages and overview cover the third.